These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36039718)

  • 1. [Ten questions about transthyretin amyloidosis].
    Giovannetti A; Accietto A; Massa P; Leone O; Guaraldi P; Saturi G; Caponetti AG; Sguazzotti M; Ponziani A; Gagliardi C; Galiè N; Cortelli P; Longhi S; Biagini E
    G Ital Cardiol (Rome); 2022 Sep; 23(9):676-685. PubMed ID: 36039718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin amyloid cardiomyopathy.
    Garcia-Pavia P; Domínguez F; Gonzalez-Lopez E
    Med Clin (Barc); 2021 Feb; 156(3):126-134. PubMed ID: 33138983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update in 'wild-type' transthyretin cardiac amyloidosis: Clinical guide for its diagnosis and treatment.
    Herrador L; Yun S; González-Costello J
    Med Clin (Barc); 2024 Aug; 163(3):e36-e43. PubMed ID: 38762347
    [No Abstract]   [Full Text] [Related]  

  • 8. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiac amyloidosis : simplifying the diagnosis of a complex disease].
    Dayer N; Monney P; Hugelshofer S
    Rev Med Suisse; 2024 May; 20(875):1010-1017. PubMed ID: 38783670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
    Vaishnav J; Brown E; Sharma K
    Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
    Brito D; Albrecht FC; de Arenaza DP; Bart N; Better N; Carvajal-Juarez I; Conceição I; Damy T; Dorbala S; Fidalgo JC; Garcia-Pavia P; Ge J; Gillmore JD; Grzybowski J; Obici L; Piñero D; Rapezzi C; Ueda M; Pinto FJ
    Glob Heart; 2023; 18(1):59. PubMed ID: 37901600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unravelling transthyretin cardiac amyloidosis: updates on diagnosis, treatment, and prevalence insights.
    Disabato G; Attanasio A; Guida G; Piepoli M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1418-1419. PubMed ID: 38593200
    [No Abstract]   [Full Text] [Related]  

  • 17. Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy.
    Muller SA; Oerlemans MIFJ
    Eur J Heart Fail; 2023 Jun; 25(6):854-856. PubMed ID: 37191114
    [No Abstract]   [Full Text] [Related]  

  • 18. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis: an update on diagnosis, current therapy, and future directions.
    Khedraki R
    Curr Opin Cardiol; 2022 May; 37(3):272-284. PubMed ID: 35612939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.